Company: REVB
Filing Date: 2025-09-16
Form Type: S-3
Source: 0001193125-25-205145
Chunk: 16

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-16
Form: S-3
Chunk 16
---
-287423) filed with the SEC on May 23, 2025.

We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any document incorporated by reference. Requests should be addressed to Corporate Secretary, 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122 or via telephone at (650) 800-3717.

You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with different information. You should not assume that the information contained in this prospectus or the accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date.

Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form 8-K.

<div align='center'>12</div>

PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution (1) . The following are the estimated expenses of the distribution of the shares registered hereunder on Form S-3:

| Registration Fee-Securities and Exchange Commission | $ |  4,001 |
| Accountants Fees and Expenses                       | $ | 15,000 |
| Legal Fees and Expenses                             | $ | 55,000 |
| Miscellaneous                                       | $ |  5,000 |
| Total                                               | $ | 79,001 |

(1) The amounts set forth below, except for the SEC Registration Fee, are estimated.

<div align='center'>13</div>

As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our Charter and amended and restated bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a